Table 2B

Association between type of prior oral anticoagulant use and endpoints

EndpointPrior NOACPrior VKANo prior OACNOAC vs no OACVKA vs no OACP value
KM% (events)KM% (events)KM% (events)Adj. HR (95% CI)*Adj. HR (95% CI)*
Primary endpoint
ISTH major/CRNM bleeding
 At 30 days5.1 (60)5.1 (51)5.9 (131)0.80 (0.58 to 1.10)0.84 (0.60 to 1.17)0.33
 At 180 days12.8 (144)14.2 (137)13.5 (288)0.93 (0.76 to 1.14)1.03 (0.83 to 1.27)0.70
ISTH major bleeding
 At 30 days1.1 (13)1.7 (17)1.8 (39)0.48 (0.24 to 0.95)0.84 (0.47 to 1.51)0.11
 At 180 days3.8 (41)4.7 (45)4.3 (90)0.78 (0.53 to 1.15)1.02 (0.71 to 1.48)0.39
Intracranial bleeding
 At 30 days0.0 (0)0.0 (0)0.2 (4)---------
 At 180 days0.5 (5)0.6 (5)0.4 (9)0.91 (0.30 to 2.76)1.01 (0.33 to 3.07)0.98
Definite/probable stent thrombosis
 At 30 days0.7 (8)0.3 (3)0.7 (16)0.92 (0.39 to 2.17)0.47 (0.14 to 1.63)0.49
 At 180 days0.7 (9)0.5 (5)0.8 (18)0.92 (0.41 to 2.08)0.67 (0.25 to 1.82)0.73
All-cause death or rehospitalisation
 At 30 days10.1 (124)8.1 (83)10.8 (250)0.92 (0.74 to 1.15)0.77 (0.60 to 0.99)0.12
 At 180 days27.6 (332)24.6 (251)25.4 (580)1.07 (0.93 to 1.22)0.95 (0.82 to 1.11)0.40
All-cause death or ischaemic event
 At 30 days2.0 (25)1.3 (13)2.8 (65)0.74 (0.46 to 1.18)0.46 (0.25 to 0.85)0.03
 At 180 days5.5 (66)5.2 (53)7.6 (171)0.74 (0.56 to 0.96)0.65 (0.47 to 0.88)0.009
Cardiovascular death
 At 30 days0.6 (7)0.6 (6)0.9 (20)0.69 (0.29 to 1.66)0.70 (0.28 to 1.77)0.61
 At 180 days2.0 (24)1.9 (19)2.9 (67)0.67 (0.42 to 1.06)0.55 (0.33 to 0.93)0.04
Stroke
 At 30 days0.2 (2)0.2 (2)0.4 (9)0.48 (0.10 to 2.26)0.58 (0.12 to 2.76)0.57
 At 180 days1.0 (11)0.5 (5)1.0 (23)1.01 (0.49 to 2.11)0.47 (0.185 to 1.25)0.29
Myocardial infarction
 At 30 days1.2 (15)0.6 (6)1.7 (39)0.76 (0.41 to 1.39)0.37 (0.16 to 0.89)0.08
 At 180 days2.7 (32)2.9 (29)4.0 (89)0.73 (0.48 to 1.09)0.74 (0.48 to 1.13)0.18
  • HRs in the ‘at 30 days’ rows include events from randomisation to 30 days. HRs in the ‘at 180 days’ rows include events from randomisation to 180 days.

  • *Adjusted by age, sex, race, hypertension, heart failure, diabetes, prior stroke, TIA or thromboembolism, qualifying index event and time from index event to randomisation.

  • CRNM, clinically relevant non-major; ISTH, International Society on Thrombosis and Haemostasis; KM, Kaplan-Meier; NOAC, non-vitamin K antagonist oral anticoagulant; TIA, transient ischaemic attack; VKA, vitamin K antagonist.